Please use this identifier to cite or link to this item: https://doi.org/10.1186/1471-2407-11-319
Title: Pilot study on developing a decision support tool for guiding re-administration of chemotherapeutic agent after a serious adverse drug reaction
Authors: Loke, P.Y.
Chew, L. 
Yap, C.W. 
Issue Date: 28-Jul-2011
Citation: Loke, P.Y., Chew, L., Yap, C.W. (2011-07-28). Pilot study on developing a decision support tool for guiding re-administration of chemotherapeutic agent after a serious adverse drug reaction. BMC Cancer 11 : -. ScholarBank@NUS Repository. https://doi.org/10.1186/1471-2407-11-319
Abstract: Background: Currently, there are no standard guidelines for recommending re-administration of a chemotherapeutic drug to a patient after a serious adverse drug reaction (ADR) incident. The decision on whether to rechallenge the patient is based on the experience of the clinician and is highly subjective. Thus the aim of this study is to develop a decision support tool to assist clinicians in this decision making process.Methods: The inclusion criteria for patients in this study are: (1) had chemotherapy at National Cancer Centre Singapore between 2004 to 2009, (2) suffered from serious ADRs, and (3) were rechallenged. A total of 46 patients fulfilled the inclusion criteria. A genetic algorithm attribute selection method was used to identify clinical predictors for patients' rechallenge status. A Naïve Bayes model was then developed using 35 patients and externally validated using 11 patients.Results: Eight patient attributes (age, chemotherapeutic drug, albumin level, red blood cell level, platelet level, abnormal white blood cell level, abnormal alkaline phosphatase level and abnormal alanine aminotransferase level) were identified as clinical predictors for rechallenge status of patients. The Naïve Bayes model had an AUC of 0.767 and was found to be useful for assisting clinical decision making after clinicians had identified a group of patients for rechallenge. A platform independent version and an online version of the model is available to facilitate independent validation of the model.Conclusion: Due to the limited size of the validation set, a more extensive validation of the model is necessary before it can be adopted for routine clinical use. Once validated, the model can be used to assist clinicians in deciding whether to rechallenge patients by determining if their initial assessment of rechallenge status of patients is accurate. © 2011 Loke et al; licensee BioMed Central Ltd.
Source Title: BMC Cancer
URI: http://scholarbank.nus.edu.sg/handle/10635/106221
ISSN: 14712407
DOI: 10.1186/1471-2407-11-319
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
2011-pilot_study_developing_decision_support-published.pdf304.89 kBAdobe PDF

OPEN

PublishedView/Download

SCOPUSTM   
Citations

1
checked on Aug 11, 2018

WEB OF SCIENCETM
Citations

1
checked on Jul 25, 2018

Page view(s)

36
checked on Jul 27, 2018

Download(s)

3
checked on Jul 27, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.